{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.3","value":"7.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Blood samples will be collected by direct venipuncture during regularly scheduled visits according to the collection plan provided in the study protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Pharmacokinetic Blood Sampling: Full pharmacokinetic profile assessments on Cycle 1, Day 15 (at pre-dose and at 1h, 2h, 5h, and 24h post-dose) were performed.","id":"OG000","title":"Day 15"}],"paramType":"MEAN","populationDescription":"The pharmacokinetics population consists of all patients who have a pharmacokinetic assessment with a sufficient number of evaluable blood samples. The analsyis was limited to RAD001 + BSC arm.","reportingStatus":"POSTED","timeFrame":"At pre-dose and post-dose: 1 hour, 2 hour, 5 hour, 24 hour of Cycle 1 Day 1, Cycle 1 Day 15 and at pre-dose from Cycle 2 (Day 1) and all subsequent treatment cycles until data cut-off 28Feb2008.","title":"Pharmacokinetics of RAD001: Normalized to Body Surface Area (CL/F)","type":"SECONDARY","unitOfMeasure":"L/hour/m^2"}